In other similar MR studies, genetically-proxied inhibition of NPC1L1 was associated with higher CRC risk in the two-sample MR by Carter et al. (OR = 2.13; 1.18–3.85 per SD decrease in LDL-C; 5 SNPs as IVs) [14], but not with colon cancer risk in a one-sample MR study from Denmark that utilised a 4-SNPs risk score and included 1144 cases [21]. This evidence concerns the gene NPC1L1 and colorectal carcinoma.